{
    "Trade/Device Name(s)": [
        "EliA RF IgM Immunoassay",
        "EliA\u2122 RF IgM Immunoassay"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K182747",
    "Predicate Device Reference 510(k) Number(s)": [
        "K102673"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHR"
    ],
    "Summary Letter Date": "September 27, 2018",
    "Summary Letter Received Date": "September 28, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5775"
    ],
    "Regulation Name(s)": [
        "Rheumatoid factor immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Rheumatoid Factor IgM"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Li-heparin)",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 2500",
        "Phadia 5000"
    ],
    "Method(s)/Technology(ies)": [
        "Quantitative immunoassay",
        "Immunofluorescence measurement"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliA RF IgM quantitative immunoassay on Phadia 2500/5000 instruments for rheumatoid factor measurement",
    "Indications for Use Summary": "Intended for in vitro quantitative measurement of IgM class rheumatoid factor antibodies in human serum and plasma (Li-heparin, EDTA) to aid in the diagnosis of rheumatoid arthritis in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}